Reichardt J K, Packman S, Woo S L
Howard Hughes Medical Institute, Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030.
Am J Hum Genet. 1991 Oct;49(4):860-7.
Galactosemia is an autosomal recessive disorder of human galactose metabolism caused by deficiency of the enzyme galactose-1-phosphate uridyl transferase (GALT). The molecular basis of this disorder is at present not well understood. We report here two missense mutations which result in low or undetectable enzymatic activity. First, we identified at nucleotide 591 a transition which substitutes glutamine 188 by arginine. The mutated glutamine is not only highly conserved in evolution (conserved also in Escherichia coli and Saccharomyces cerevisiae), but is also two amino acid residues downstream from the active site histidine-proline-histidine triad and results in about 10% of normal enzymatic activity. The arginine 188 mutation is the most common galactosemia mutation characterized to date. It accounts for one-fourth of the galactosemia alleles studied. Second, we report the substitution of arginine 333 by tryptophan, caused by a transition at nucleotide 1025. The area surrounding this missense mutation is the most highly conserved domain in the homologous enzymes from E. coli, yeast, and humans, and this mutation results in undetectable enzymatic activity, suggesting that this is a severe mutation. This second mutation appears to be rare, since it was found only in the patient we sequenced. Our data provide further evidence for the heterogeneity of galactosemia at the molecular level, heterogeneity which might be related to the variable clinical outcome observed in this disorder.
半乳糖血症是一种常染色体隐性人类半乳糖代谢紊乱疾病,由半乳糖 -1- 磷酸尿苷酰转移酶(GALT)缺乏引起。目前对这种疾病的分子基础了解尚不充分。我们在此报告两个错义突变,它们导致酶活性降低或无法检测到。首先,我们在核苷酸591处鉴定出一个转换,该转换将谷氨酰胺188替换为精氨酸。突变的谷氨酰胺不仅在进化过程中高度保守(在大肠杆菌和酿酒酵母中也保守),而且位于活性位点组氨酸 - 脯氨酸 - 组氨酸三联体下游两个氨基酸残基处,导致约10%的正常酶活性。精氨酸188突变是迄今为止已鉴定出的最常见的半乳糖血症突变。它占所研究的半乳糖血症等位基因的四分之一。其次,我们报告由核苷酸1025处的转换导致的精氨酸333被色氨酸替代。这个错义突变周围区域是来自大肠杆菌、酵母和人类的同源酶中最保守的结构域,并且这个突变导致无法检测到酶活性,表明这是一个严重的突变。第二个突变似乎很罕见,因为它仅在所测序的患者中发现。我们的数据为半乳糖血症在分子水平上的异质性提供了进一步证据,这种异质性可能与该疾病中观察到的可变临床结果有关。